Skip to content
2000
image of Evaluation of Hordenine’s Therapeutic Potential in Alzheimer’s Disease-induced Cognitive and Oxidative Impairments

Abstract

Introduction

This research aimed to investigate the potential of Hordenine (HR) against Alzheimer's Disease (AD) induced by Streptozotocin (STZ) in Wistar rats by evaluating its impact on cognitive function, oxidative stress, inflammatory cytokines, and neuroprotective biomarkers in comparison to donepezil.

Methods

The study involved five groups of Wistar rats: a control group, a group with STZ-induced AD, and three treatment groups receiving varying doses of HR (50 mg/kg and 75 mg/kg) and donepezil (5 mg/kg). Over 28 days, the animals underwent various behavioural tests to assess cognitive function, along with biochemical analyses to measure A+cetylcholinesterase (AChE) activity, oxidative stress markers, inflammatory cytokines (IL-1β, TNF-α), and nuclear factor kappa B (NF-κB) levels, and histological examination. Additionally, molecular docking studies were performed to assess the interaction of HR with AChE.

Results

STZ administration caused significant cognitive decline, oxidative stress, and elevated inflammatory markers. HR supplementation, particularly at 75 mg/kg, significantly improved cognition, reduced oxidative stress, and decreased pro-inflammatory cytokines (IL-1β, TNF-α), as well as NF-κB levels, while increasing Brain-Derived Neurotrophic Factor (BDNF) expression. Molecular docking studies revealed strong binding of HR to AChE, suggesting potential inhibitory effects.

Discussion

Hordenine demonstrated promising neuroprotective effects against STZ-induced neurotoxicity by improving cognition and reducing oxidative stress and inflammation, suggesting HR’s potential as an adjunct therapy for Alzheimer's disease, offering a protective mechanism that may complement existing treatments like donepezil.

Conclusion

The research shows that the medicinal plant HR exhibits neuroprotective potential against AD induced by STZ. Further research involving clinical trials is warranted to fully establish the efficacy and safety of HR in the treatment of AD.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rafna/10.2174/012772574X389943250908070348
2025-09-29
2026-02-26

  • From This Site

    /content/journals/rafna/10.2174/012772574X389943250908070348
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Scheltens P. De Strooper B. Kivipelto M. alzheimer’s disease. Lancet 2021 397 10284 1577 1590 10.1016/S0140‑6736(20)32205‑4 33667416
    [Google Scholar]
  2. Bhatt A. Bhardwaj H. Srivastava P. Mesenchymal stem cell therapy for alzheimer’s disease: A novel therapeutic approach for neurodegenerative diseases. Neuroscience 2024 555 52 68 10.1016/j.neuroscience.2024.07.019 39032806
    [Google Scholar]
  3. Ma R. Mu Q. Xi Y. Liu G. Liu C. Nanotechnology for tau pathology in alzheimer’s disease. Mater. Today Bio 2024 27 101145 10.1016/j.mtbio.2024.101145 39070098
    [Google Scholar]
  4. Parikh D. Shah M. A comprehensive study on epigenetic biomarkers in early detection and prognosis of alzheimer’s disease. Biomed Anal 2024 1 2 138 153 10.1016/j.bioana.2024.05.005
    [Google Scholar]
  5. Eid A. Mhatre I. Richardson J.R. Gene-environment interactions in alzheimer’s disease: A potential path to precision medicine. Pharmacol. Ther. 2019 199 173 187 10.1016/j.pharmthera.2019.03.005 30877021
    [Google Scholar]
  6. Singh M.K. Shin Y. Ju S. Han S. Kim S.S. Kang I. Comprehensive Overview of alzheimer’s Disease: Etiological insights and degradation strategies. Int. J. Mol. Sci. 2024 25 13 6901 10.3390/ijms25136901 39000011
    [Google Scholar]
  7. Chavoshinezhad S. Beirami E. Izadpanah E. Feligioni M. Hassanzadeh K. Molecular mechanism and potential therapeutic targets of necroptosis and ferroptosis in alzheimer’s disease. Biomed. Pharmacother. 2023 168 115656 10.1016/j.biopha.2023.115656 37844354
    [Google Scholar]
  8. Olufunmilayo E.O. Gerke-Duncan M.B. Holsinger R.M.D. Oxidative stress and antioxidants in neurodegenerative disorders. Antioxidants 2023 12 2 517 10.3390/antiox12020517 36830075
    [Google Scholar]
  9. Vejandla B. Savani S. Appalaneni R. Veeravalli R.S. Gude S.S. Alzheimer’s disease: The past, present, and future of a globally progressive disease. Cureus 2024 16 1 e51705 10.7759/cureus.51705 38313929
    [Google Scholar]
  10. Sharma V.K. Singh T.G. Singh S. Garg N. Dhiman S. Apoptotic pathways and alzheimer’s disease: Probing therapeutic potential. Neurochem. Res. 2021 46 12 3103 3122 10.1007/s11064‑021‑03418‑7 34386919
    [Google Scholar]
  11. Skaper S.D. Facci L. Zusso M. Giusti P. An inflammation-centric view of neurological disease: Beyond the neuron. Front. Cell. Neurosci. 2018 12 72 10.3389/fncel.2018.00072 29618972
    [Google Scholar]
  12. Wang W-Y. Tan M-S. Yu J-T. Tan L. Role of pro-inflammatory cytokines released from microglia in alzheimer’s disease. Ann. Transl. Med. 2015 3 10 136 10.3978/j.issn.2305‑5839.2015.03.49 26207229
    [Google Scholar]
  13. Cai Y. Liu J. Wang B. Sun M. Yang H. Microglia in the neuroinflammatory pathogenesis of alzheimer’s disease and related therapeutic targets. Front. Immunol. 2022 13 856376 10.3389/fimmu.2022.856376 35558075
    [Google Scholar]
  14. Lee J.K. Kim N.J. Recent advances in the inhibition of p38 MAPK as a potential strategy for the treatment of alzheimer’s disease. Molecules 2017 22 8 1287 10.3390/molecules22081287 28767069
    [Google Scholar]
  15. Oliveira S.L.B. Pillat M.M. Cheffer A. Lameu C. Schwindt T.T. Ulrich H. Functions of neurotrophins and growth factors in neurogenesis and brain repair. Cytometry A 2013 83A 1 76 89 10.1002/cyto.a.22161 23044513
    [Google Scholar]
  16. Xu Q. Ji X.F. Chi T.Y. Sigma 1 receptor activation regulates brain-derived neurotrophic factor through NR2A-CaMKIV-TORC1 pathway to rescue the impairment of learning and memory induced by brain ischaemia/reperfusion. Psychopharmacology 2015 232 10 1779 1791 10.1007/s00213‑014‑3809‑6 25420607
    [Google Scholar]
  17. Armstrong R.A. What causes alzheimer’s disease? Folia Neuropathol. 2013 51 3 169 188 10.5114/fn.2013.37702 24114635
    [Google Scholar]
  18. Cheignon C. Tomas M. Bonnefont-Rousselot D. Faller P. Hureau C. Collin F. Oxidative stress and the amyloid beta peptide in alzheimer’s disease. Redox Biol. 2018 14 450 464 10.1016/j.redox.2017.10.014 29080524
    [Google Scholar]
  19. Yan Z. Feng J. alzheimer’s disease: Interactions between cholinergic functions and β-amyloid. Curr. Alzheimer Res. 2004 1 4 241 248 10.2174/1567205043331992 15975053
    [Google Scholar]
  20. Khalili M. Kiasalari Z. Rahmati B. Narenjkar J. Behavioral and histological analysis of crocus sativus effect in intracerebroventricular streptozotocin model of alzheimer disease in rats. Iran. J. Pathol. 2010 5 1 27 33
    [Google Scholar]
  21. Walczak-Nowicka Ł.J. Herbet M. Acetylcholinesterase inhibitors in the treatment of neurodegenerative diseases and the role of acetylcholinesterase in their pathogenesis. Int. J. Mol. Sci. 2021 22 17 9290 10.3390/ijms22179290 34502198
    [Google Scholar]
  22. Tata A. Velluto L. D’Angelo C. Reale M. Cholinergic system dysfunction and neurodegenerative diseases: Cause or effect? CNS Neurol. Disord. Drug Targets 2014 13 7 1294 1303 10.2174/1871527313666140917121132 25230223
    [Google Scholar]
  23. Luo X. Lauwers M. Layer P.G. Wen C. Non-neuronal role of acetylcholinesterase in bone development and degeneration. Front. Cell Dev. Biol. 2021 8 620543 10.3389/fcell.2020.620543 33585459
    [Google Scholar]
  24. Xie H.Q. Ma Y. Fu H. New perspective on the regulation of acetylcholinesterase via the aryl hydrocarbon receptor. J. Neurochem. 2021 158 6 1254 1262 10.1111/jnc.15261 33278027
    [Google Scholar]
  25. Agrawal M. Singhal M. Semwal B.C. Neuroprotective action of hordenine against the Aluminium Chloride (AlCl3) induced alzheimer’s diseases & associated memory impairment in experimental rats. Pharmacol Res Mod Chin Med 2024 12 100492 10.1016/j.prmcm.2024.100492
    [Google Scholar]
  26. Hahn M. Lindemann V. Behrens M. Permeability of dopamine D2 receptor agonist hordenine across the intestinal and blood-brain barrier in vitro. PLoS One 2022 17 6 e0269486 10.1371/journal.pone.0269486 35709159
    [Google Scholar]
  27. Su Y. Liu Y. He D. Hordenine inhibits neuroinflammation and exerts neuroprotective effects via inhibiting NF-κB and MAPK signaling pathways in vivo and in vitro. Int. Immunopharmacol. 2022 108 108694 10.1016/j.intimp.2022.108694 35349959
    [Google Scholar]
  28. Kim S.C. Lee J.H. Kim M.H. Hordenine, a single compound produced during barley germination, inhibits melanogenesis in human melanocytes. Food Chem. 2013 141 1 174 181 10.1016/j.foodchem.2013.03.017 23768344
    [Google Scholar]
  29. Zhang X. Du L. Zhang J. Li C. Zhang J. Lv X. Hordenine protects against lipopolysaccharide-induced acute lung injury by inhibiting inflammation. Front. Pharmacol. 2021 12 712232 10.3389/fphar.2021.712232 34539399
    [Google Scholar]
  30. Hassan S.T.S. Shedding light on the effect of natural anti-herpesvirus alkaloids on SARS-CoV-2: A treatment option for COVID-19. Viruses 2020 12 4 476 10.3390/v12040476 32340120
    [Google Scholar]
  31. Bai R. Guo J. Ye X.Y. Xie Y. Xie T. Oxidative stress: The core pathogenesis and mechanism of alzheimer’s disease. Ageing Res. Rev. 2022 77 101619 10.1016/j.arr.2022.101619 35395415
    [Google Scholar]
  32. Bretträger M. Becker T. Gastl M. Screening of mycotoxigenic fungi in barley and barley malt (Hordeum vulgare L.) using real-time PCR—A comparison between molecular diagnostic and culture technique. Foods 2022 11 8 1149 10.3390/foods11081149 35454736
    [Google Scholar]
  33. Bouhlal O. Affricot J.R. Puglisi D. Malting quality of ICARDA elite winter barley (hordeum vulgare l.) germplasm grown in moroccan middle atlas. J. Am. Soc. Brew. Chem. 2022 80 4 401 412 10.1080/03610470.2021.1978036
    [Google Scholar]
  34. Singh K. Gupta J.K. Kumar S. Pharmacological and therapeutic potential of hordeum vulgare. Pharmacol Res Mod Chin Med 2023 8 100300 10.1016/j.prmcm.2023.100300
    [Google Scholar]
  35. Yao X. Yao Y. An L. Accumulation and regulation of anthocyanins in white and purple Tibetan Hulless Barley (Hordeum vulgare L. var. nudum Hook. f.) revealed by combined de novo transcriptomics and metabolomics. BMC Plant Biol. 2022 22 1 391 10.1186/s12870‑022‑03699‑2 35922757
    [Google Scholar]
  36. Raj R. Shams R. Pandey V.K. Dash K.K. Singh P. Bashir O. Barley phytochemicals and health promoting benefits: A comprehensive review. J Agric Food Res 2023 14 100677 10.1016/j.jafr.2023.100677
    [Google Scholar]
  37. Rao G.S. Identity of peyocactin, an antibiotic from peyote (Lophophora williamsii), and hordenine. J. Pharm. Pharmacol. 1970 22 7 544 545 10.1111/j.2042‑7158.1970.tb10566.x 4395066
    [Google Scholar]
  38. Akhtar A. Dhaliwal J. Sah S.P. 7,8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance. Psychopharmacology 2021 238 7 1991 2009 10.1007/s00213‑021‑05826‑7 33774703
    [Google Scholar]
  39. Sharma A. Singh T. Pathak D. Virmani T. Kumar G. Alhalmi A. Antidepressive‐like effect of aegle marmelos leaf extract in chronic unpredictable mild stress‐induced depression‐like behaviour in rats. BioMed Res. Int. 2022 2022 1 6479953 10.1155/2022/6479953 36593774
    [Google Scholar]
  40. Antunes M. Biala G. The novel object recognition memory: Neurobiology, test procedure, and its modifications. Cogn. Process. 2012 13 2 93 110 10.1007/s10339‑011‑0430‑z 22160349
    [Google Scholar]
  41. Kudrinskaya V.M. Ivlev A.P. Obukhova D.A. Spatial memory impairment is associated with decreased dopamine-β-hydroxylase activity in the brains of rats exposed to manganese chloride. Toxicol. Mech. Methods 2024 34 9 1035 1044 10.1080/15376516.2024.2379012 39021086
    [Google Scholar]
  42. Faizan M. Jahan I. Ishaq M. Neuroprotective effects of trigonelline in kainic acid-induced epilepsy: Behavioral, biochemical, and functional insights. Saudi Pharm. J. 2023 31 12 101843 10.1016/j.jsps.2023.101843 37961069
    [Google Scholar]
  43. Pohanka M. Hrabinova M. Kuca K. Simonato J.P. Assessment of acetylcholinesterase activity using indoxylacetate and comparison with the standard ellman’s method. Int. J. Mol. Sci. 2011 12 4 2631 2640 10.3390/ijms12042631 21731462
    [Google Scholar]
  44. Sussman J.L. Harel M. Frolow F. Atomic structure of acetylcholinesterase from torpedo californica: A prototypic acetylcholine-binding protein. Science 1991 253 5022 872 879 10.1126/science.1678899 1678899
    [Google Scholar]
  45. Pettersen E.F. Goddard T.D. Huang C.C. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004 25 13 1605 1612 10.1002/jcc.20084 15264254
    [Google Scholar]
  46. Kim S. Chen J. Cheng T. PubChem 2019 update: Improved access to chemical data. Nucleic Acids Res. 2019 47 D1 D1102 D1109 10.1093/nar/gky1033 30371825
    [Google Scholar]
  47. Bauer M.R. Mackey M.D. Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein–ligand complexes. J. Med. Chem. 2019 62 6 3036 3050 10.1021/acs.jmedchem.8b01925 30807144
    [Google Scholar]
  48. Athilli L. Balasubramaniam A. Appala Raju N. Evaluation of compound hordenine (hordeum vulgare): In vitro, gene expression, and molecular modeling investigations. Res J Pharm Technol 2024 17 6 2561 2567 10.52711/0974‑360X.2024.00400
    [Google Scholar]
  49. Anwar S. Mohammad T. Shamsi A. Discovery of hordenine as a potential inhibitor of pyruvate dehydrogenase kinase 3: Implication in lung cancer therapy. Biomedicines 2020 8 5 119 10.3390/biomedicines8050119 32422877
    [Google Scholar]
  50. Morris G.M. Huey R. Lindstrom W. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009 30 16 2785 2791 10.1002/jcc.21256 19399780
    [Google Scholar]
  51. Zaafar D. Elghazawy N.H. Hassan A. Mahmoud M.Y. Bakr A.F. Arafa R.K. Unleashing new MTDL AChE and BuChE inhibitors as potential anti-AD therapeutic agents: In vitro, in vivo and in silico studies. Int. J. Biol. Macromol. 2024 268 Pt 1 131740 10.1016/j.ijbiomac.2024.131740 38653428
    [Google Scholar]
  52. Xu Z. Zhang Q. Ding C. Beneficial effects of hordenine on a model of ulcerative colitis. Molecules 2023 28 6 2834 10.3390/molecules28062834 36985809
    [Google Scholar]
  53. Li Y. Vogel C. Kalinichenko L.S. The beer component hordenine inhibits alcohol addiction‐associated behaviours in mice. Addict. Biol. 2023 28 8 e13305 10.1111/adb.13305 37500485
    [Google Scholar]
  54. Su S. Cao M. Wu G. Hordenine protects against hyperglycemia-associated renal complications in streptozotocin-induced diabetic mice. Biomed. Pharmacother. 2018 104 315 324 10.1016/j.biopha.2018.05.036 29775900
    [Google Scholar]
  55. Xie Y. Li X. Xu D. Hordenine alleviates lipopolysaccharide-induced mastitis by suppressing inflammation and oxidative stress, modulating intestinal microbiota, and preserving the blood–milk barrier. J. Agric. Food Chem. 2024 72 39 21503 21519 10.1021/acs.jafc.4c02867 39289834
    [Google Scholar]
  56. Li H. Gao M. Chen Z. Hordenine improves Parkinsonian‐like motor deficits in mice and nematodes by activating dopamine D2 receptor‐mediated signaling. Phytother. Res. 2023 37 8 3296 3308 10.1002/ptr.7790 36883794
    [Google Scholar]
  57. Peitzika S.C. Pontiki E. A review on recent approaches on molecular docking studies of novel compounds targeting acetylcholinesterase in alzheimer disease. Molecules 2023 28 3 1084 10.3390/molecules28031084 36770750
    [Google Scholar]
/content/journals/rafna/10.2174/012772574X389943250908070348
Loading
Evaluation of Hordenine’s Therapeutic Potential in Alzheimer’s Disease-induced Cognitive and Oxidative Impairments
Bentham Science Publishers ; https://doi.org/10.2174/012772574X389943250908070348
/content/journals/rafna/10.2174/012772574X389943250908070348
/content/journals/rafna/10.2174/012772574X389943250908070348
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: Alzheimer’s disease ; oxidative stress ; Hordenine ; streptozotocin ; Donepezil ; neuroinflammation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test